Clinical trials: Drug Interactions
Alcohol Drinking
Naltrexone and Memantine Effects on Alcohol Drinking Behaviors
The purpose of this study is to evaluate the combined effects of the study medications naltrexone and memantine on alcohol drinking behaviors.
- Trial name
- NCT01519063
- Testing
- Naltrexone and memantine first
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Yale University
Healthy
A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.
- Trial name
- NCT02804399
- Testing
- PF-06463922, rifampin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Adverse Drug Interactions
Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse drug-drug interactions (DDIs) are responsible for approximately 3% of all hospitalizations in the US, perhaps costing more than $1.3 billion per year.
- Trial name
- NCT00621309
- Testing
- Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Washington
Pulmonary Arterial Hypertension
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
The development of disease-targeted medication for the treatment of pulmonary arterial hypertension (PAH) has significantly improved within the last years, leading to the development of 10 approved agents.
- Trial name
- EPIC (NCT02484807)
- Testing
- no intervention, only observation of different groups
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Heidelberg University
Healthy
Drug Interaction Study of Digoxin and BI 10773
The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and…
- Trial name
- NCT01306175
- Testing
- Digoxin plus BI 10773, Digoxin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Anthrax
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909…
- Trial name
- NCT04067011
- Testing
- Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
- Where
- 4 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Healthy
This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other
The primary objective of this trial is to investigate the effect of multiple doses of ethinylestradiol / levonorgestrel (Microgynon®) on single dose pharmacokinetics of BI 409306 and the effect of single dose of BI 409306 on…
- Trial name
- NCT03193307
- Testing
- Microgynon® 30, BI 409306
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
The study investigated the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with…
- Trial name
- DDI (NCT04308304)
- Testing
- MK-1942, Donepezil
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Efavirenz, Metabolism and Pharmacokinetics Changes
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
The purpose of this study is to see if administration of medicines and genetic differences affects the activity of a liver enzyme called CYP2B6 in healthy volunteers.
- Trial name
- NCT01104376
- Testing
- Efavirenz, voriconazole
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV Prevention, Transgender Health
Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
Truvada (Emtricitabine or FTC and tenofovir disoproxil fumarate or TDF) has been approved for HIV prevention since 2012. Drug concentrations after receipt of oral Truvada for HIV Pre Exposure Prophylaxis (or PrEP) appeared to be…
- Trial name
- I-BrEATHe (NCT04050371)
- Testing
- 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Healthy
Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus
The primary objective of this trial is to investigate the effect of multiple-dose faldaprevir (FDV) on the single-dose pharmacokinetics of cyclosporine or tacrolimus
- Trial name
- NCT02016625
- Testing
- Faldaprevir, Cyclosporine, Tacrolimus
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV-1-infection, Solid Organ Transplant
Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
The aims of this study are to obtain pharmacokinetic data on interactions between dolutegravir (DTG) and immunosuppressant drugs (Cyclosporine A, Tacrolimus, Sirolimus and Mycophenolic acid) in solid organ transplant (SOT)…
- Trial name
- NCT03360682
- Testing
- Lamivudine 300 MG, Abacavir 600 MG, Dolutegravir 50 mg
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Premature Birth
Fathers and Late Preterm Babies Study
The purpose of this study is to test an educational intervention for first-time fathers of late preterm (34 to 36 weeks gestation) infants.
- Trial name
- FLPTB (NCT01056653)
- Testing
- Standard Dose, High Dose, Comparison Group
- Where
- Canada
- Volunteers
- 113 people
- Sponsor
- University of Calgary
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events.
- Conditions
- Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
- Trial name
- NCT01241903
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Susan Smyth
Healthy
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects
The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
- Trial name
- NCT02341482
- Testing
- PF-04958242, Itraconazole
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Volunteers
Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
The purpose of this study is to characterize the safety, tolerability and plasma pharmacokinetic (PK) profile of TAK-915 when administered as single and multiple oral suspension doses at escalating dose levels in healthy…
- Trial name
- NCT02461160
- Testing
- TAK-915 suspension, Midazolam, TAK-915 tablet
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP 2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of…
- Trial name
- NCT00960570
- Testing
- Efavirenz 600 mg, Fenofibric Acid
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.